Antisoma PLC Reports Survival Advantage For AS1404 In Lung Cancer And Regains Product Rights
Antisoma announces the presentation at ASCO of positive data from a phase II lung cancer study of its vascular disrupting agent AS1404 (DMXAA). Patients receiving AS1404 in addition to standard chemotherapy showed increased tumour response rates, longer time to disease progression and enhanced survival compared with patients receiving standard chemotherapy alone.